Physician profile
Hardeep Bal
NPI 1053525568
$7,587.46
in general payments reported to CMS, 2019-2025
43 companies · $1,122 in 2025
The $1,122 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $970 · 2020: $474 · 2021: $1,917 · 2022: $841 · 2023: $1,003 · 2024: $1,261 · 2025: $1,122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,386.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,386.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,329.24 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Biohaven Pharmaceuticals, INC. | $1,243.17 | 2021 | |
| Lilly USA, LLC | $633.22 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $590.72 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $511.11 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $277.53 | 2019-2025 | |
| Abbott Laboratories | $238.92 | 2020-2025 | Freestyle Libre 3 |
| Abbvie INC. | $215.55 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $200.90 | 2021-2025 | Xifaxan, Trulance |
| Amgen INC. | $199.52 | 2019-2025 | Repatha, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $187.14 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $186.56 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.54 | 2019-2025 | Jardiance |
| Esperion Therapeutics, INC. | $150.19 | 2022-2025 | Nexletol |
| Exact Sciences Corporation | $130.68 | 2023-2025 | Cologuard Collection Kit |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hardeep Bal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.